Bayer Healthcare China

Bayer Healthcare
Dr. Min Pang
Alliance Manager 

D2M Biotherapeutics United States

A human-genetics driven next generation immunity-oncology company
Nan Bing
CEO 
Functionality

Dao Tun GmbH Switzerland

Dao Tun is a consulting company, founded in 2019, specialised in cross-border collaboration between Europe and China, primarily in the healthcare and life science industry.
Dao Tun is based in the Basel region, one of the world's leading clusters for Pharma and Life Sciences and also part of the trinational Biovalley region (Switzerland, Germany, France).
Dao Tun team provides customised strategy and execution plan via in-depth interview and targeted research; quickly gains insights into the association and matching between potential partners to make accurate and effective connections; simplifies the processes, reduces the cost of communication, and establishes the trust with full care.
Dao Tun is a bridge builder who excels at understanding and interpreting their interests and needs, and aligning perspectives of different stakeholders and across cultures for win-win-win situation.

Dr. Tianke Wang
Dr. Tianke Wang
CEO 
Functionality

Focus-X Therapuetics United States

Focus-X is a preclinical stage biotech company committed to the Discovery and development,, of personalized precision medicine fulfilling the unmet needs in cancer diagnosis and treatment. We are to release the true potential of radioligand therapy by leveraging our world class peptide drug discovery platform and joining force with top radiopharmaceutical partners.
Company Size (Fulltime employees)
Partnering Objectives
Please specify your partnering goal
Connection to investors and partners
Headquartner in China
Biotech/Pharma Asset Stage
Fa Liu
CEO 
Functionality

GCV Life India

Life science-focused Innovation licensing organizations looking to commercialize global innovations for the Indian and South Asian markets through a unique partnership-led model.
Dr. Chirag Jain
Analyst 
Functionality

Hengenix United States

Innovative biologics for cancer and other patients' unmet needs
Website:
Hengenix.com
Company Size (Fulltime employees)
Year of foundation
2010
Partnering Objectives
Please specify your partnering goal
co-dev
Headquartner in China
Wenfeng Xu
VP Research 

Hetero Biopharma India

We are into Mabs - Biosimilars
Company Size (Fulltime employees)
Partnering Objectives
Please specify your partnering goal
We are in need of ample amount of fund to proceed with clinical trials for one of our projects ...and we are looking for partners for help us achieve this goal
Headquartner in China
Mr. Mani Arjun
Research associate 

Jiangsu Hengrui Medicine Co.,Ltd. China

Founded in 1970, Jiangsu Hengrui Medicine Co., Ltd. (JHM) is the largest publicly listed and a leading biopharma based in China with 24,700 employees devoted to empowering healthier lives through research. With over $3.3 billion in revenue in 2019, JHM has 6 new molecular entities approved in China as well as 30+ programs in clinical development in China, US, and Australia across oncology, anesthesiology & analgesics, autoimmune, and metabolic & cardiovascular therapeutic areas. Driven by internal R&D and global licensing and collaboration, JHM is committed to bring high quality products to patients.
Company Size (Fulltime employees)
Year of foundation
50 years
Partnering Objectives
Please specify your partnering goal
In-licensing clinical stage assets for China market; out-licensing ex-China rights of Hengrui assets
Headquartner in China
Assets Information 1
Please see the link below for our pipeline. Most of our assets are out-licensing candidates|https://www.hengruius.com/pipeline.html||China, US and global (please check with us for detailed info)
Ms. Linda Zhao
Head, US BD Team 
Functionality

Mesa Verde Venture Partners United States

Life Sciences venture capital fund with three funds under management.
Mr. Randy Berholtz
Senior Advisor 
Functionality